Boston Scientific (BSX) Registers a Bigger Fall Than the Market: Important Facts to Note
Boston Scientific (BSX) closed the most recent trading day at $44.95, moving 4.2% from the previous trading session.
BSX - Boston Scientific Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$82.90
DETAILS
HIGH:
$120.00
LOW:
$55.00
MEDIAN:
$76.00
CONSENSUS:
$82.90
UPSIDE:
83.04%
Stock News
Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
Boston Scientific's shares have fallen over 50% year to date as the medtech company continues to walk back full-year 2026 guidance. Sell-side analysts remain relatively upbeat on the stock.
Boston Scientific: The Market Is Pricing A Broken Compounder-We See A Reset One
Boston Scientific has experienced a ~53% collapse over twelve months, driven by guidance cuts, WATCHMAN deceleration, EP share loss, and a mixed CHAMPION-AF readout. FY26 guidance was cut to 6.5-8.0% organic growth and $3.34-$3.41 EPS, with management tempering long-term 10%+ growth expectations. BSX trades at a significant discount to peers (12.6x FY27E P/E), despite maintaining a robust ~8% revenue and ~10-11% EPS growth profile.
Belo Sun Announces Management Transition
TORONTO, June 08, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (TSX: BSX) (OTCQX: BSXGF) (the “Company” or “Belo Sun”) today announced a change to its in-country executive leadership team as the Volta Grande Gold Project advances toward its next phase of development. The Company announced that Adriano Espeschit will no longer serve as President, Brazil.
Boston Scientific (BSX) Rises Higher Than Market: Key Facts
Boston Scientific (BSX) concluded the recent trading session at $48.85, signifying a +2.43% move from its prior day's close.
Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Why These Three Big Buybacks Are Sending Very Different Signals to Investors
Share buybacks are one of the key ways that companies express confidence in their outlook. This is particularly true when shares take a large hit, as management teams look to retire shares at what they may believe is a depressed price.
Belo Sun Announces Corporate Update
TORONTO, June 01, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (TSX: BSX) (OTC: BSXGF) (the “Company” or “Belo Sun”) provides the following updates regarding a recent petition filed by the Brazilian Federal Prosecution Service (“MPF”) in civil public action No. 1002764-28.2025.4.01.3903 before the Federal Court of Altamira, Pará, Brazil.
Zscaler, AutoZone, And Regencell Are Among Top 10 Large-Cap Losers Last Week (May 25-May 29): Are The Others In Your Portfolio?
Weak guidance, analyst target cuts and declining energy prices weighed on Zscaler, AutoZone, PDD Holdings and other large-cap stocks, making them last week's biggest losers.
Boston Scientific Corporation (BSX) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Boston Scientific Corporation (BSX) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
BSX vs. ABT: Which Medical Stock Has More Upside Potential?
Boston Scientific and Abbott both posted solid quarterly growth, but analysts see stronger upside for Boston Scientific despite mounting operational pressures.
Why Boston Scientific Stock Was Sliding This Week
Sales of a key product line will likely be flat this quarter and next, company management said.
Boston Scientific (BSX) Stock Dips While Market Gains: Key Facts
Boston Scientific (BSX) concluded the recent trading session at $49.11, signifying a -2.68% move from its prior day's close.
This Boston Scientific Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Here Are Thursday’s Top Wall Street Analyst Research Calls: Agilent, Boston Scientific, Comfort Systems, Dick’s Sporting Goods, Dominion Energy, Electronic Arts, First Solar, Trade Desk, Valvoline, and More
Pre-Market Stock Futures: Futures are trading lower on Thursday as new records are set almost daily, with the AI/Data center trade continuing to push stocks higher on Wednesday. All four major indices hit or closed Wednesday's session at record highs, with the legacy Dow Jones Industrial Average leading the way, up 0.36% at 50,664, setting... Here Are Thursday's Top Wall Street Analyst Research Calls: Agilent, Boston Scientific, Comfort Systems, Dick's Sporting Goods, Dominion Energy, Electronic Arts, First Solar, Trade Desk, Valvoline, and More
Butterfield Announces Agreement to Acquire Control of CIBC Caribbean in $1.8 Billion Transaction
The Bank of N.T. Butterfield and Son Limited (âButterfieldâ) (NYSE: NTB | BSX: NTB.BH) has entered into a definitive agreement to acquire CIBC's 91.7% intere
Stock Market Today, May 27: Boston Scientific Plunges After Reiterating Underwhelming Full Year Growth Guidance
Investors weigh softer WATCHMAN and urology demand against a still-active device pipeline and capital deployment moves, today, May 27, 2026.
Boston Scientific Is Betting $1.5 Billion on a Massive Market -- and Wall Street Is Paying Attention
The medical device giant just opened its wallet for a stake in a privately held company with a groundbreaking product.
BSX Fairly Valued by DCF at $51
On May 27, 2026, we delve into the DCF analysis for Boston Scientific Corp (BSX), a company currently facing significant price performance challenges. Over the
Belo Sun Announces 2026 Shareholder Meeting Voting Results and Corporate Update
TORONTO, May 26, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX:BSX OTCQX:BSXGF) today is pleased to announce that each of the six individuals nominated for election as a director of Belo Sun at the Company's Annual and Special Meeting of Shareholders held on May 26, 2026 (the “Meeting”), was elected.
Price Targets
Boston Scientific price target lowered to $65 from $90 at Piper Sandler
$65.00
(was $47.17)
Piper Sandler
Boston Scientific price target lowered to $64 from $85 at Truist
$64.00
(was $49.34)
Truist Financial
Boston Scientific price target lowered to $65 from $80 at BTIG
$65.00
(was $47.68)
Marie Thibault
·
BTIG
Boston Scientific price target lowered to $70 from $71 at Canaccord
$70.00
(was $48.31)
Canaccord Genuity
Boston Scientific price target lowered to $71 from $81 at Goldman Sachs
$71.00
(was $50.46)
Goldman Sachs
Boston Scientific price target lowered to $70 from $75 at Baird
$70.00
(was $50.46)
Robert W. Baird
Boston Scientific (BSX) PT Lowered to $74 at Leerink
$74.00
(was $50.46)
Mike Kratky
·
Leerink Partners
Boston Scientific price target lowered to $89 from $96 at Barclays
$89.00
(was $50.46)
Barclays
Boston Scientific downgraded to Equal Weight from Overweight at Wells Fargo
$55.00
(was $50.46)
Larry Biegelsen
·
Wells Fargo
Boston Scientific price target lowered to $75 from $85 at Stifel
$75.00
(was $51.07)
Rick Wise
·
Stifel Nicolaus
Boston Scientific price target lowered to $75 from $78 at Baird
$75.00
(was $55.92)
Robert W. Baird
Boston Scientific downgraded to Neutral from Outperform at Daiwa
$60.00
(was $58.45)
Daiwa
Boston Scientific price target lowered to $100 from $105 at RBC Capital
$100.00
(was $65.80)
RBC Capital
Boston Scientific price target lowered to $90 from $100 at Oppenheimer
$90.00
(was $65.72)
Oppenheimer
Boston Scientific price target lowered to $71 from $109 at Canaccord
$71.00
(was $64.87)
William Plovanic
·
Canaccord Genuity
Boston Scientific price target lowered to $77 from $97 at Needham
$77.00
(was $64.87)
Mike Matson
·
Needham
Boston Scientific price target lowered to $85 from $90 at Truist
$85.00
(was $64.87)
Truist Financial
Boston Scientific price target lowered to $78 from $86 at Baird
$78.00
(was $64.87)
Robert W. Baird
Boston Scientific price target lowered to $75 from $94 at Wells Fargo
$75.00
(was $64.87)
Wells Fargo
Boston Scientific price target lowered to $96 from $100 at Barclays
$96.00
(was $64.87)
Matt Miksic
·
Barclays